+

WO2002014369A3 - Human kininogen d5 domain polypeptides and their use - Google Patents

Human kininogen d5 domain polypeptides and their use Download PDF

Info

Publication number
WO2002014369A3
WO2002014369A3 PCT/US2001/023185 US0123185W WO0214369A3 WO 2002014369 A3 WO2002014369 A3 WO 2002014369A3 US 0123185 W US0123185 W US 0123185W WO 0214369 A3 WO0214369 A3 WO 0214369A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
domain polypeptides
human kininogen
kininogen
human
Prior art date
Application number
PCT/US2001/023185
Other languages
French (fr)
Other versions
WO2002014369A2 (en
WO2002014369A9 (en
Inventor
Andrew P Mazar
Jose C Juarez
Original Assignee
Attenuon Llc
Andrew P Mazar
Jose C Juarez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon Llc, Andrew P Mazar, Jose C Juarez filed Critical Attenuon Llc
Priority to AU2001277119A priority Critical patent/AU2001277119A1/en
Priority to EP01954904A priority patent/EP1305342A2/en
Priority to JP2002519506A priority patent/JP2004515222A/en
Publication of WO2002014369A2 publication Critical patent/WO2002014369A2/en
Publication of WO2002014369A3 publication Critical patent/WO2002014369A3/en
Publication of WO2002014369A9 publication Critical patent/WO2002014369A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

Peptides form the human kininogen D5 domain and fusion peptides thereof having angiogenesis-inhibitory activity. These peptides are used in diagnosis and therapy of diseases associated with endothelial cell migration and proliferation, e.g., the treatment of cancer. The invention further relates to nucleic acid molecules encoding said peptides, antibodies to the said peptides and methods for isolating said peptides and cells expressing them.
PCT/US2001/023185 2000-07-24 2001-07-24 Human kininogen d5 domain polypeptides and their use WO2002014369A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2001277119A AU2001277119A1 (en) 2000-07-24 2001-07-24 Human kininogen d5 domain polypeptides and their use
EP01954904A EP1305342A2 (en) 2000-07-24 2001-07-24 Human kininogen d5 domain polypeptides and their use
JP2002519506A JP2004515222A (en) 2000-07-24 2001-07-24 Human kininogen D5 domain polypeptides and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22019400P 2000-07-24 2000-07-24
US60/220,194 2000-07-24

Publications (3)

Publication Number Publication Date
WO2002014369A2 WO2002014369A2 (en) 2002-02-21
WO2002014369A3 true WO2002014369A3 (en) 2002-09-12
WO2002014369A9 WO2002014369A9 (en) 2003-04-03

Family

ID=22822460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/023185 WO2002014369A2 (en) 2000-07-24 2001-07-24 Human kininogen d5 domain polypeptides and their use

Country Status (4)

Country Link
EP (1) EP1305342A2 (en)
JP (1) JP2004515222A (en)
AU (1) AU2001277119A1 (en)
WO (1) WO2002014369A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004527242A (en) 2001-02-05 2004-09-09 イノベンタス プロジェクト アクチボラゲット Histidine-rich glycoprotein
US7378386B2 (en) 2002-07-15 2008-05-27 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives
AU2012201537B2 (en) * 2002-07-15 2014-06-05 Board Of Regents, The University Of Texas System Peptides binding to phosphatidylethanolamine and their use in treating viral infections and cancer
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
GB0821721D0 (en) * 2008-11-27 2008-12-31 Hansa Medical Ab Antimicrobial therapy
WO2014194259A1 (en) * 2013-05-30 2014-12-04 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Methods and compositions for treating brain diseases
WO2016004281A1 (en) * 2014-07-03 2016-01-07 Chunlei Liu Polypeptides comprising a thermal sensitive ion channel linked to a domain 5 of kininogen, nucleic acids, and their uses for cell modulation and treatments

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023094A2 (en) * 1998-10-16 2000-04-27 Immunex Corporation Methods of inhibiting platelet activation and recruitment
WO2000027866A1 (en) * 1998-11-10 2000-05-18 Temple University - Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023094A2 (en) * 1998-10-16 2000-04-27 Immunex Corporation Methods of inhibiting platelet activation and recruitment
WO2000027866A1 (en) * 1998-11-10 2000-05-18 Temple University - Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by high molecular weight kininogen and peptide analogs thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HASAN AAK ET AL.: "Mapping the Cell Binding Site on High Molecular Weight Kininogen Domain 5", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 33, 18 August 1995 (1995-08-18), pages 19256 - 19261, XP002200416 *
HERWALD H ET AL.: "Isolation and Characterization of the Kininogen-binding Protein p33 from Endothelial Cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 22, 31 May 1996 (1996-05-31), pages 13040 - 13047, XP002200475 *
KUNAPULI SP ET AL.: "Deletion Mutagenesis of High Molecular Weight Kininogen Light Chain", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 4, 5 February 1993 (1993-02-05), pages 2486 - 2492, XP002200848 *
ZHANG J-C ET AL.: "Two-chain high molecular weight kininogen induces endothelial cell apoptosis and inhibits angiogenesis: partial activity within domain 5", FASEB JOURNAL, vol. 14, December 2000 (2000-12-01), pages 2589 - 2600, XP002200415 *

Also Published As

Publication number Publication date
JP2004515222A (en) 2004-05-27
AU2001277119A1 (en) 2002-02-25
EP1305342A2 (en) 2003-05-02
WO2002014369A2 (en) 2002-02-21
WO2002014369A9 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
ATE405650T1 (en) PRODUCTION OF WHOLE ANTIBODIES IN PROKARYONTIC CELLS
MXPA05010830A (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2.
DK1005540T3 (en) IKK-beta proteins, nucleic acids and methods
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
MXPA02000192A (en) Compositions and methods for the therapy and diagnosis of lung cancer.
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2001034802A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
CY1108459T1 (en) AKT-3 NUCLEAR ACIDS, POLYPALPTESES, AND THEIR USES
EP0815202A4 (en) Human tissue inhibitor of metalloproteinase-4
DK0750672T3 (en) DNA sequences for matrix metal proteases, their generation and use
DE69819124D1 (en) LYOPHILIZATION OF CULTIVATED, HUMAN CELLS FOR THE PRESERVATION OF RNA AND DNA
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
WO2004094476A3 (en) Compositions and methods relating to stop-1
EE05293B1 (en) RG1 pol Peptide Binding Antibody, Immunoconjugate Included, and Use thereof
MXPA03000979A (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.
BR0012765A (en) Peptide, methods of making an antibody, making a binding agent capable of binding to a cell form of a prion protein, removing a cell form of a prion protein from a sample, and using an antibody and / or binding agent, antibody, binding agent, use of an antibody or binding agent, kit, and, peptide sequence of a cellular form of a prion protein
WO2002000878A3 (en) Human msp1 mitochondrial dynamin, its msp1-x isoforms, and their therapeutic use
WO2000043510A3 (en) Ras activator nucleic acid molecules - guanine nucleotide releasing factor grf4, polypeptides and methods of use
WO2003020911A3 (en) Human schizophrenia gene
WO1998054209A3 (en) Human mast cell function-associated antigen (mafa) and uses thereof
DK1196188T3 (en) VGF-selective monoclonal antibodies and their use in the treatment of VGF-related disorders
WO2002044366A3 (en) Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379
DE602005021159D1 (en) BACTERIOPHAGE AND PROPHAGEN PROTEINS IN CANCER THERAPY

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2001954904

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/5-5/5, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2001954904

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载